Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
The Prostate2006Vol. 66(16), pp. 1768–1778
Citations Over Time
John T. Isaacs, Роберто Пили, David Z. Qian, Susan L. Dalrymple, Jason B. Garrison, Natasha Kyprianou, Anders Björk, Anders Olsson, Tomas Leanderson
Abstract
Based upon its robust and consistent anti-angiogenic activity and thus tumor growth, ABR-215050 has entered clinical trials for the treatment of prostate cancer.
Related Papers
- → Uncomfortably high: Testing reveals inflated THC potency on retail Cannabis labels(2023)39 cited
- → The potency of bovine PPD tuberculins in guinea-pigs and in tuberculous cattle(1983)18 cited
- → Establishment of a Potency Test by ELISA for a Rabies Vaccine for Animal Use in Japan(2003)15 cited
- → Potency analysis of cellular therapies: the role of molecular assays(2021)
- → Application of Emax model to assess the potency of topical corticosteroid products(2022)